Alliance for Aging Research’s Post

4/2/24: Transforming Tricuspid Valve Care: FDA Gives Green Light to Abbott’s TriClip™ - "The U.S. approval of #TriClip is a significant advancement for people suffering from #tricuspidregurgitation, a #heart condition that negatively impacts their quality of life and puts them at grave risk of serious health issues," said Paul Sorajja, M.D., the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center for the Minneapolis Heart Institute Foundation and director of the Center for Valve and Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital and co-principal investigator of the TRILUMINATE™ Pivotal trial. "With TriClip, physicians can offer patients a therapy option backed by excellent safety and effectiveness to help restore tricuspid native valve performance without subjecting them to high-risk open-heart surgery that may not be feasible for individuals with TR who are generally older and sicker." More at https://lnkd.in/esDjzMFT

While varicose veins can be uncomfortable and unsightly, patients who suffer from them have several minimally invasive treatment choices today. One of the most recently developed options is the VenaSeal closure system from Medtronic, which was approved for use by the Food and Drug Administration in 2015. VenaSeal uses a medical adhesive to seal off and collapse the diseased vein, which reroutes blood flow through nearby healthy veins. This specially formulated vein glue (the same type of adhesive that's been used in medical procedures since the 1950s, as an alternative to sutures) stays soft even after sealing off the vein, so you won't be able to feel it. It has great success rates, with a high vein closure rate. In a recent clinical study, 94.6% of patients treated with VenaSeal still had closed veins five years after their treatment. Best of all, what makes VenaSeal stand out from other treatments is that no compression stocking is needed, so you can exercise without restriction immediately following the procedure. No anesthesia is needed, no incisions are needed, and the discomfort related to both the procedure itself as well as discomfort during the recovery are less than with the other procedures out there. Visit our website at https://lnkd.in/ea6_hZVi to learn more and see if VenaSeal treatment is right for you. The Vascular Care Group is a leading independent group of board-certified vascular surgeons with extensive experience treating vascular disease including arterial and venous disease, vascular malformations and anomalies, fibroids, and pelvic venous disease. We offer a comprehensive range of testing and advanced treatment options in our state-of-the-art office-based labs and nationally accredited vein centers across New England. 𝗪𝗢𝗥𝗟𝗗 𝗖𝗟𝗔𝗦𝗦 𝗩𝗔𝗦𝗖𝗨𝗟𝗔𝗥 𝗖𝗔𝗥𝗘 𝗜𝗡 𝗬𝗢𝗨𝗥 𝗖𝗢𝗠𝗠𝗨𝗡𝗜𝗧𝗬. 𝗖𝗢𝗠𝗙𝗢𝗥𝗧𝗔𝗕𝗟𝗘. 𝗖𝗢𝗡𝗩𝗘𝗡𝗜𝗘𝗡𝗧. 𝗖𝗢𝗠𝗣𝗥𝗘𝗛𝗘𝗡𝗦𝗜𝗩𝗘.

This is an interesting study, as right sided endocarditis is becoming more frequent with possibly severe sequels. This percutaneous approach appears surely attractive, as it avoids more invasive surgery. However are the results very preliminary. The vegetations have been reduced significantly and accordingly, temperature and WBC count have decreased. However were vegetations still left with a size of ~ 7mm and we know from other studies that lesions >10 mm are a critical size for less favourable clinical courses mid- and longterm. We see no midterm, not even short term data, for example concerning recurrencies and so we can only say that this percutaneous approach is feasible. Further data must be awaited and until then the surgical approach still remains the gold standard.

🚀 Transforming Carotid Revascularization: TCAR's Rise in the US (2015-2019) 🔬 Study by David Stonko, Earl Goldsborough, Pavel Kibrik, George Zhang, Courtenay Holscher, Caitlin Hicks reveals significant shifts in carotid revascularization techniques. 📊 Key Findings: Analysis of over 108,000 patients from the Vascular Quality Initiative database. Transcarotid artery revascularization (TCAR) use increased remarkably since its FDA approval in 2015. Carotid endarterectomy (CEA) remains common but has seen a decrease in use. TCAR has become increasingly preferred for patients at high risk for stroke and other complications. https://lnkd.in/d-czK2pd #HealthcareInnovation #VascularSurgery #TCAR #MedicalResearch #PatientCare #CarotidRevascularization #cme

https://lnkd.in/ey_i372T Promising findings for the treatment of peripheral artery disease 🦵🏼 Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM #interventionalcardiology #interventionalradiology #vascularsurgery

Nearly 1 out of 9 patients treated for Proliferative Diabetic Retinopathy (PDR) are Lost to Follow up in the United States. Our research that utilized the powerful American Academy of Ophthalmology IRIS Clinical Registry examined 73,595 eyes of 56,590 patients with PDR managed in the United States. Surprisingly, there was NO significant differences in the Loss to Follow Up rates among those treated with anti-VEGF, PRP or combination. The paper came out online in Ophthalmology Retina. Thanks to Jay Wang Sen Zhang Charles Li Flora Lum who were involved in the project. #blindness #diabeticretinopathy #diabetes #adherence #compliance https://lnkd.in/gAE4DycW

https://lnkd.in/gjuvQZMj our article in #DCR underscoring the need for #venousthromboembolism #VTE prophylaxis in #inflammatoryboweldisease ....in this paper #UC patients exposed to #tofacitinib at the time of surgery had a 3x increased risk of 90-day postoperative VTE... Tara Russell MD MPH PhD Crohn's & Colitis Foundation Diseases of the Colon & Rectum...should we be sending all postoperative #IBD patients home on #VTE prophylaxis?

📃Scientific paper: Whole ureter replacement with Yang–Monti principle: successful treatment of challenging conditions Abstract: Background No clear consensus has been reached on the reconstruction of long-segment or total ureter discontinuation. Here we present our experience using the Yang–Monti technique in total ureter reconstruction. Methods This study was a single-center retrospective study of patients who underwent Yang–Monti ileal whole ureter reconstruction (from the ureteropelvic junction[UPJ] to the ureterovesical junction). Data were collected on patients’ baseline characteristics, stricture etiology, the time interval between insult and surgical repair, pre/postoperative serum creatinine, estimated glomerular filtration rate (eGFR), split renal function, complications during admission and follow-ups, and the indwelling durations of JJ tubes and nephrostomy tubes, if presented. Results Seven patients underwent Yang–Monti ileal ureter reconstruction in 2010–2020 at our hospital. One of the patients underwent single-session bilateral ureter repair. Radiation therapy-related fibrosis and degloving injury were the most common etiologies for ureter injury. The median interval between ureter insult and operation was 8 months. The median follow-up was 36.7 months. The average operation time was 11.4 h, and the average blood loss was 273 ml. Postoperatively, no significant differences were found in serum creatinine, eGFR, or split renal function. As for postoperative complications, two patients experienced ileus and were treated conservatively. One patient had UPJ stenosis, which reso... Continued on ES/IODE ➡️ https://etcse.fr/9bixU ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

The use of intravenous indocyanine green in minimally invasive segmental lung resections: a systematic review Background: To identify intersegmental planes (ISPs) in video/robot-assisted thoracoscopic segmentectomies, indocyanine green (ICG) is commonly used. The aim of this systematic review is to evaluate the efficacy of intravenous ICG in the identification of ISP. Methods: A systematic search was performed. Studies evaluating patients who underwent a video/robot-assisted thoracoscopic segmentectomy using intravenous ICG were included. The primary outcome measure was the frequency and percentage of patients in whom the ISP was adequately visualized. Secondary outcomes encompassed the ICG dose, time to visualization, time to maximum ICG visualization, time to disappearance of ICG effect and adverse reactions to ICG. Results: Eighteen studies were included for systematic review, enrolling a total of 1,090 patients. Irrespective of the injected dose, intravenous ICG identified the ISP in 94% of the cases (range, 30-100%). Overall, there was a considerable amount of heterogeneity regarding the injected dose of ICG (range, 5-25 mg or 0.05-0.5 mg/kg). The mean time before first effect of ICG was visible ranged from 10 to 40 seconds. The mean total time of ICG visibility ranged from 90 to 140 seconds after a bolus injection and was 170 seconds after continuous infusion. No adverse reactions were reported. Conclusions: After administration of intravenous ICG, visualization of the ISP is successful in up to 94% of cases, even after administration of a low dose (0.05 mg/kg) of ICG. The use of intravenous ICG is safe with no reported adverse effects in the immediate peri-operative period. https://lnkd.in/eqrXcj29 Maxim Peeters Yanina Jansen Jean Daemen Lori van Roozendaal Paul De Leyn Karel Hulsewé Yvonne Vissers MD PhD Erik de Loos #ICG #indocyaninegreen #guidedsurgery #fluorescence #fluorescent #surgery #surgeon #surgical #thinkgreen #imaging #patients #safety

Just this week, the North Carolina State Health Plan discontinued coverage of GLP-1 therapeutics for weight loss, while maintaining coverage for bariatric surgery for individuals with obesity.   This decision highlights how insurers are reevaluating the cost-effectiveness of GLP-1 medications for weight loss compared to established interventions like bariatric surgery or the less invasive endoscopic sleeve gastroplasty (ESG) we offer at our practice.   While proven, endoscopic bariatric therapies are too often left out of these discussions. It’s refreshing to see this important mention of endoscopic sleeve gastroplasty as a cost-effective option for the treatment of obesity, offering reduced risk and abbreviated recovery. https://lnkd.in/e-6NB2sz